Acetylshikonin exerts anti-tumor effects on non-small cell lung cancer through dual inhibition of STAT3 and EGFR

Acetylshikonin Induces Apoptosis in Human Colorectal Cancer HCT-15 and LoVo Cells via Nuclear Translocation of FOXO3 and ROS Level Elevation

(2021) Heui Min Lim et al.   Oxidative Medicine and Cellular Longevity

EGFR mutation mediates resistance to EGFR tyrosine kinase inhibitors in NSCLC: From molecular mechanisms to clinical research

(2021) Rui-Fang Dong et al.   PHARMACOLOGICAL RESEARCH

Lung cancer

(2021) Alesha A Thai et al.   LANCET

STAT3 as a mediator of oncogenic cellular metabolism: Pathogenic and therapeutic implications

(2021) Isidora Tošić et al.   NEOPLASIA

Feedback activation of EGFR is the main cause for STAT3 inhibition-irresponsiveness in pancreatic cancer cells

(2020) Chengguang Zhao et al.   ONCOGENE

Rhein shows potent efficacy against non-small-cell lung cancer through inhibiting the STAT3 pathway

(2019) Lehe Yang et al.   Cancer Management and Research

Rhein sensitizes human pancreatic cancer cells to EGFR inhibitors by inhibiting STAT3 pathway

(2019) Lehe Yang et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Acetylshikonin stimulates glucose uptake in L6 myotubes via a PLC-β3/PKCδ-dependent pathway

(2019) Wendong Huang et al.   BIOMEDICINE & PHARMACOTHERAPY

Rhein sensitizes human colorectal cancer cells to EGFR inhibitors by inhibiting STAT3 pathway

(2019) Yan Zhuang et al.   OncoTargets and Therapy

Betacellulin drives therapy-resistance in glioblastoma

(2019) QiWen Fan et al.   NEURO-ONCOLOGY

Dihydroartemisinin suppresses STAT3 signaling and Mcl-1 and Survivin expression to potentiate ABT-263-induced apoptosis in Non-small Cell Lung Cancer cells harboring EGFR or RAS mutation

(2018) Xiaohui Yan et al.   BIOCHEMICAL PHARMACOLOGY

Targeting the IL-6/JAK/STAT3 signalling axis in cancer

(2018) Daniel E. Johnson et al.   Nature Reviews Clinical Oncology

Inverse Correlation of STAT3 and MEK Signaling Mediates Resistance to RAS Pathway Inhibition in Pancreatic Cancer

(2018) Nagaraj S Nagathihalli et al.   CANCER RESEARCH

Alantolactone sensitizes human pancreatic cancer cells to EGFR inhibitors through the inhibition of STAT3 signaling

(2018) Hailun Zheng et al.   MOLECULAR CARCINOGENESIS

Lung cancer: current therapies and new targeted treatments

(2017) Fred R Hirsch et al.   LANCET

Emerging functions of the EGFR in cancer

(2017) Sara Sigismund et al.   Molecular Oncology

Feedback Activation of STAT3 as a Cancer Drug-Resistance Mechanism

(2016) Chengguang Zhao et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Adaptive Upregulation of EGFR Limits Attenuation of Tumor Growth by Neutralizing IL6 Antibodies, with Implications for Combined Therapy in Ovarian Cancer

(2015) C. S. Milagre et al.   CANCER RESEARCH

Dovitinib and erlotinib in patients with metastatic non-small cell lung cancer: A drug–drug interaction

(2015) Millie Das et al.   LUNG CANCER

FDA-approved small-molecule kinase inhibitors

(2015) Peng Wu et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Drug Resistance via Feedback Activation of Stat3 in Oncogene-Addicted Cancer Cells

(2014) Ho-June Lee et al.   CANCER CELL

Acetylshikonin, a Novel AChE Inhibitor, Inhibits Apoptosis via Upregulation of Heme Oxygenase-1 Expression in SH-SY5Y Cells

(2013) Yan Wang et al.   Evidence-based Complementary and Alternative Medicine

The ErbB/HER family of protein-tyrosine kinases and cancer

(2013) Robert Roskoski   PHARMACOLOGICAL RESEARCH

Lithospermum erythrorhizon Suppresses High-Fat Diet-Induced Obesity, and Acetylshikonin, a Main Compound of Lithospermum erythrorhizon, Inhibits Adipocyte Differentiation

(2012) So Young Gwon et al.   JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY

Shikonin derivatives inhibited LPS-induced NOS in RAW 264.7 cells via downregulation of MAPK/NF-κB signaling

(2008) Yu Wen Cheng et al.   JOURNAL OF ETHNOPHARMACOLOGY